An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV

University of Oxford14 个研究点分布在 1 个国家目标入组 2,130 人开始时间: 2020年6月24日最近更新: 2020年11月27日

适应症

试验速览

阶段: 1 期
发起方: University of Oxford
入组人数: 2,130
试验地点: 14
主要终点: Assess humoral immunogenicity of ChAdOx1 nCoV-19 in people living with HIV

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

A Phase I/II, double-blinded, placebo-controlled, individually randomized trial to assess safety, immunogenicity and efficacy of the candidate Coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults aged 18-65 years living with and without HIV in South Africa. The vaccine or placebo will be administered via an intramuscular injection into the deltoid muscle of the non-dominant arm.

详细描述

A total of 2070 participants will be enrolled into the trial; 1970 HIV-uninfected and 100 people living with HIV. There will be 4 trial groups, group 1 (n=50; intensive safety & immunogenicity cohort, HIV negative), group 2a (n=250; safety, intense immunogenicity & efficacy), group 2b (n=1650; safety, immunogenicity & vaccine efficacy) and group 3 (n=100, intensive safety & immunogenicity cohort, HIV positive).

Participants will be followed up for 12 months after enrollment.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Prevention
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

Double-blinded, placebo controlled. Pharmacist and vaccine administrators will be unblinded only. DSMB will be unblinded if required to assess safety signal

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•Healthy adults aged 18-65 years.
•Documented result of not being infected with HIV (including screening by a rapid HIV antibody test) within two weeks of randomization into the study for Group-1 and Group-2 participants only.
•Able and willing (in the Investigator's opinion) to comply with all study requirements.
•Willing to allow investigators review available medical records, and review all medical and laboratory records if participant is admitted to hospital with respiratory tract infection suspected or confirmed to be COVID-
•For females only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening (within 14 days of randomization) or vaccination.
•For Group-3 only (i.e. HIV-infected), need to have been on anti-retroviral treatment for at least three months and HIV-1 viral load is <1,000 copies/ml within two weeks of randomization.
•Agreement to refrain from blood donation during the course of the study.
•Provide written informed consent.

排除标准

•Planned receipt of any vaccine other (licensed or investigational) than the study intervention within 30 days before and after each study vaccination.
•Use of any unproven registered and unregistered treatments for COVID-
•Prior receipt of an investigational or licensed vaccine likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus vaccines).
•Administration of immunoglobulins and/ or any blood products within the three months preceding the planned administration of the vaccine candidate.
•HBSAg positivity on the screening sample.
•Grade 2 or higher level of abnormality for FBC, U&E or LFT based on DAIDS Grading Criteria (Version 2.1, July 2017)
•History of allergic disease or reactions likely to be exacerbated by any component of the ChAdOx1 nCoV-19 vaccine.
•Any history of hereditary angioedema or idiopathic angioedema.
•Any history of anaphylaxis in relation to vaccination.
•Pregnancy, lactation or willingness/intention to become pregnant during the study.
•History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
•History of serious psychiatric condition likely to affect participation in the study.
•Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture.
•Any other serious chronic illness requiring hospital specialist supervision.
•Chronic respiratory diseases, including asthma
•Chronic cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness
•Seriously overweight (BMI ≥ 40 Kg/m2)
•Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week.
•Suspected or known injecting drug abuse in the 5 years preceding enrollment.
•Any clinically significant abnormal finding on screening urinalysis.
•Any other significant disease, disorder or finding which may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study or impair interpretation of the study data.
•History of laboratory confirmed COVID-19 illness or known contact with a person that was infected with SARS-COV-
•New onset of fever or a cough or shortness of breath in the 30 days preceding screening and/or enrollment
•Travel history to any other country with widespread epidemic since January 2020
•In addition to above, Group 1 & 2 participants need to fulfill the following exclusion criteria: Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent severe infections and chronic use (more than 14 days) immunosuppressant medication within the past 6 months ( topical steroids are allowed).
•Any confirmed or suspected immunosuppressive or immunodeficient state (except HIV infection for Group-3), asplenia, recurrent severe infections and chronic use (more than 14 days) immunosuppressant medication within the past 6 months (topical steroids are allowed).